Drug Profile


Alternative Names: RGH-896; UCB-3491

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gedeon Richter
  • Developer Forest Laboratories; Gedeon Richter; PRA Health Sciences; UCB
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Infantile spasms
  • Phase I Epilepsy; Pain
  • Preclinical Parkinson's disease
  • Discontinued Neuropathic pain

Most Recent Events

  • 01 Sep 2017 Phase-I/II clinical trials in Infantile spasms in Belgium, United Kingdom (PO) (NCT02829827)
  • 11 Jul 2016 UCB Biopharma plans a phase I/II trial for Infantile spasms in Belgium and United Kingdom (PO) (NCT02829827)
  • 16 Feb 2016 Preclinical data released by UCB Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top